Current studies suggest that the negative regulator of ferroptosis, metallothionein-1g (MT-1G) (Sun et al., 2016a), the activation of nuclear factor erythroid 2-related factor 2 (NRF2) (Sun et al., 2016b), and the transcription factor yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) all inhibit ferroptosis (Gao et al., 2021), which may be the main mechanism of drug resistance in the treatment of HCC by sorafenib (Nie et al., 2018). Here, MT1G is linked to hepatocellular carcinoma.